Show simple item record

dc.contributor.authorHarrison, PT
dc.contributor.authorHuang, PH
dc.date.accessioned2018-08-03T08:35:19Z
dc.date.issued2018-10-26
dc.identifier.citationEssays in biochemistry, 2018, 62 (4), pp. 583 - 593
dc.identifier.issn0071-1365
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2245
dc.identifier.eissn1744-1358
dc.identifier.doi10.1042/ebc20180016
dc.description.abstractDrug resistance remains one of the greatest challenges facing precision oncology today. Despite the vast array of resistance mechanisms that cancer cells employ to subvert the effects of targeted therapy, a deep understanding of cancer signalling networks has led to the development of novel strategies to tackle resistance both in the first-line and salvage therapy settings. In this review, we provide a brief overview of the major classes of resistance mechanisms to targeted therapy, including signalling reprogramming and tumour evolution; our discussion also focuses on the use of different forms of polytherapies (such as inhibitor combinations, multi-target kinase inhibitors and HSP90 inhibitors) as a means of combating resistance. The promise and challenges facing each of these polytherapies are elaborated with a perspective on how to effectively deploy such therapies in patients. We highlight efforts to harness computational approaches to predict effective polytherapies and the emerging view that exceptional responders may hold the key to better understanding drug resistance. This review underscores the importance of polytherapies as an effective means of targeting resistance signalling networks and achieving durable clinical responses in the era of personalised cancer medicine.
dc.formatPrint-Electronic
dc.format.extent583 - 593
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectProtein Kinase Inhibitors
dc.subjectSalvage Therapy
dc.subjectSystems Biology
dc.subjectSignal Transduction
dc.subjectDrug Resistance, Neoplasm
dc.subjectHSP90 Heat-Shock Proteins
dc.titleExploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance.
dc.typeJournal Article
dcterms.dateAccepted2018-07-10
rioxxterms.versionofrecord10.1042/ebc20180016
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-10-26
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEssays in biochemistry
pubs.declined2018-08-03T07:10:48.388+0100
pubs.issue4
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.publication-statusPublished
pubs.volume62
pubs.embargo.termsNo embargo
icr.researchteamMolecular and Systems Oncologyen_US
dc.contributor.icrauthorHarrison, Peteren
dc.contributor.icrauthorHuang, Paulen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0